阿帕替尼联合替吉奥治疗一线化疗失败晚期食管鳞癌的临床效果
|
摘要
目的观察阿帕替尼联合替吉奥治疗一线化疗失败晚期食管鳞癌的临床效果。方法选取2016年6月至2017年6月郑州大学第一附属医院收治的50例一线化疗失败晚期食管鳞癌患者,按摸球法分为对照组和观察组,各25例。对照组接受替吉奥化疗,观察组接受阿帕替尼联合替吉奥化疗。随访1 a,分析两组患者短期疗效的客观缓解率(ORR)和疾病控制率(DCR)、生存率、不良反应发生情况。结果观察组DCR、ORR[88.0%(22/25)、44.0%(11/25)]高于对照组[64.0%(16/25)、16.0%(4/25)],差异有统计学意义(P<0.05)。中位随访时间为16.5个月,观察组中位生存期为24.5个月,对照组中位生存期为16.9个月,观察组1年生存率(64.0%)高于对照组(36.0%),差异有统计学意义(P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论阿帕替尼联合替吉奥治疗一线化疗失败晚期食管鳞癌临床效果显著,值得临床推广应用。
Objective To observe the clinical effect of apatinib combined with tegafur in the treatment of advanced esophageal squamous cell carcinoma with failure of first-line chemotherapy.Methods Fifty patients with advanced esophageal squamous cell carcinoma who failed first-line chemotherapy admitted to the First Affiliated Hospital of Zhengzhou University from June of 2016 to June of 2017 were selected. The patients were divided into two groups according to touching ball method, and twenty-five cases were in each group. Control group received tegafur chemotherapy. Observation group received apatinib combined with tegafur chemotherapy. The patients were followed for one year. The objective response rates(ORR) and disease control rates(DCR) of short-term efficacy, survival rates, and adverse reactions of two groups were analyzed.Results The DCR, ORR rates of observation group [88.0%(22/25)、44.0%(11/25)] were higher than those of control group [64.0%(16/25)、16.0%(4/25)], and the differences were statistically significant(P<0.05). The median follow-up time was 16.5 months. The median survival time of observation group was 24.5 months, and the median survival time of control group was 16.9 months. The one-year survival rate of observation group(64.0%) was higher than that of observation group(36.0%), and the difference was statistically significant(P<0.05). The adverse reactions of two groups were compared, and the differences were not statistically significant(P>0.05).Conclusion The clinical effect of apatinib combined with tegafur in the treatment of advanced esophageal squamous cell carcinoma with failure of first-line chemotherapy is remarkable, which is worthy of clinical popularizing and application.
Objective To observe the clinical effect of apatinib combined with tegafur in the treatment of advanced esophageal squamous cell carcinoma with failure of first-line chemotherapy.Methods Fifty patients with advanced esophageal squamous cell carcinoma who failed first-line chemotherapy admitted to the First Affiliated Hospital of Zhengzhou University from June of 2016 to June of 2017 were selected. The patients were divided into two groups according to touching ball method, and twenty-five cases were in each group. Control group received tegafur chemotherapy. Observation group received apatinib combined with tegafur chemotherapy. The patients were followed for one year. The objective response rates(ORR) and disease control rates(DCR) of short-term efficacy, survival rates, and adverse reactions of two groups were analyzed.Results The DCR, ORR rates of observation group [88.0%(22/25)、44.0%(11/25)] were higher than those of control group [64.0%(16/25)、16.0%(4/25)], and the differences were statistically significant(P<0.05). The median follow-up time was 16.5 months. The median survival time of observation group was 24.5 months, and the median survival time of control group was 16.9 months. The one-year survival rate of observation group(64.0%) was higher than that of observation group(36.0%), and the difference was statistically significant(P<0.05). The adverse reactions of two groups were compared, and the differences were not statistically significant(P>0.05).Conclusion The clinical effect of apatinib combined with tegafur in the treatment of advanced esophageal squamous cell carcinoma with failure of first-line chemotherapy is remarkable, which is worthy of clinical popularizing and application.
引文
[1] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] 赵鹏飞, 曹邦伟. 阿帕替尼治疗胃癌及其他肿瘤的研究现状[J]. 临床与病理杂志, 2016, 36(6): 815-823.
[3] 丁婕, 戴旭, 孟宪运, 等. 实体瘤疗效评价标准的研究进展[J]. 中国肿瘤临床与康复, 2015(9): 1150-1152.
[4] 陈万青, 郑荣寿, 张思维, 等. 2012年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2016, 25(1): 1-8.
[5] CHEN W, ZHENG R, ZHANG S, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level[J]. Chin J Cancer Res, 2017, 29(1): 1-10.
[6] PENNATHUR A, GIBSON M K, JOBE B A, et al. Oesophageal carcinoma[J]. Lancet, 2013, 381(9864): 400-412.
[7] 匡菁, 杨家梅. 阿帕替尼联合二线化疗方案在晚期甲胎蛋白阳性胃癌中的临床疗效观察[J]. 实用医学杂志, 2018, 34(5): 810-813.
[8] 帖晓静, 申凤乾, 屈福莲, 等. 阿帕替尼联合替吉奥二线治疗复发转移食管鳞癌疗效的初探[J]. 中国肿瘤生物治疗杂志, 2017, 1(11): 1315-1319.
[9] 王今, 梁琳, 杜瀛瀛. 多靶点分子靶向药的皮肤不良反应与干预措施[J]. 中国临床保健杂志, 2017, 20(4): 449-451.
[2] 赵鹏飞, 曹邦伟. 阿帕替尼治疗胃癌及其他肿瘤的研究现状[J]. 临床与病理杂志, 2016, 36(6): 815-823.
[3] 丁婕, 戴旭, 孟宪运, 等. 实体瘤疗效评价标准的研究进展[J]. 中国肿瘤临床与康复, 2015(9): 1150-1152.
[4] 陈万青, 郑荣寿, 张思维, 等. 2012年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2016, 25(1): 1-8.
[5] CHEN W, ZHENG R, ZHANG S, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level[J]. Chin J Cancer Res, 2017, 29(1): 1-10.
[6] PENNATHUR A, GIBSON M K, JOBE B A, et al. Oesophageal carcinoma[J]. Lancet, 2013, 381(9864): 400-412.
[7] 匡菁, 杨家梅. 阿帕替尼联合二线化疗方案在晚期甲胎蛋白阳性胃癌中的临床疗效观察[J]. 实用医学杂志, 2018, 34(5): 810-813.
[8] 帖晓静, 申凤乾, 屈福莲, 等. 阿帕替尼联合替吉奥二线治疗复发转移食管鳞癌疗效的初探[J]. 中国肿瘤生物治疗杂志, 2017, 1(11): 1315-1319.
[9] 王今, 梁琳, 杜瀛瀛. 多靶点分子靶向药的皮肤不良反应与干预措施[J]. 中国临床保健杂志, 2017, 20(4): 449-451.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |